{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:40:24Z","timestamp":1792176024402,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11596-024-2916-9","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:03:10Z","timestamp":1724853790000},"page":"1081-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Qiliqiangxin Alleviates Imbalance of Inflammatory Cytokines in Patients with Dilated Cardiomyopathy: A Randomized Controlled Trial"],"prefix":"10.1007","volume":"44","author":[{"given":"Yu-hua","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-juan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-chao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-feng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-tao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Chinese Myocarditis & Cardiomyopathy Cooperation Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"23","key":"2916_CR1","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","volume":"37","author":"YM Pinto","year":"2016","unstructured":"Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic nondilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J, 2016,37(23):1850\u20131858","journal-title":"Eur Heart J"},{"issue":"17","key":"2916_CR2","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res, 2023,118(17):3272\u20133287","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2916_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"HP Schultheiss","year":"2019","unstructured":"Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers, 2019,5(1):32","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"2916_CR4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cardfail.2008.02.016","volume":"14","author":"JM Lapp\u00e9","year":"2008","unstructured":"Lapp\u00e9 JM, Pelfrey CM, Tang WH. Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy. J Card Fail, 2008,14(16):521\u2013530","journal-title":"J Card Fail"},{"issue":"4","key":"2916_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11596-008-0408-y","volume":"28","author":"Z Wang","year":"2008","unstructured":"Wang Z, Liao Y, Yuan J, et al. Analysis of specific Th1\/Th2 helper cell responses and IgG subtype antibodies in anti-CD4 monoclonal antibody treated mice with autoimmune cardiomyopathy. J Huazhong Univ Sci Technolog Med Sci, 2008,28(4):409\u2013414","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"2916_CR6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2006.08.024","volume":"554","author":"J Li","year":"2007","unstructured":"Li J, Leschka S, Rutschow S, et al. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur J Pharmacol, 2007,554:60\u201368","journal-title":"Eur J Pharmacol"},{"key":"2916_CR7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0065-2776(08)00604-4","volume":"99","author":"D Cihakova","year":"2008","unstructured":"Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol, 2008,99:95\u2013114","journal-title":"Adv Immunol"},{"issue":"7","key":"2916_CR8","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.4049\/jimmunol.1001718","volume":"185","author":"J Yuan","year":"2010","unstructured":"Yuan J, Yu M, Lin QW, et al. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol, 2010,185(7):4004\u20134010","journal-title":"J Immunol"},{"issue":"2","key":"2916_CR9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10875-009-9355-z","volume":"30","author":"J Yuan","year":"2010","unstructured":"Yuan J, Cao AL, Yu M, et al. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J Clin Immunol, 2010,30(2):226\u2013234","journal-title":"J Clin Immunol"},{"issue":"10","key":"2916_CR10","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.109.213157","volume":"106","author":"GC Baldeviano","year":"2010","unstructured":"Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res, 2010,106(10):1646\u20131655","journal-title":"Circ Res"},{"issue":"3","key":"2916_CR11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.intimp.2009.11.010","volume":"10","author":"J Yuan","year":"2010","unstructured":"Yuan J, Yu M, Lin QW, et al. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. Int Immunopharmacol, 2010,10(3):272\u2013276","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2916_CR12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10875-005-4187-y","volume":"25","author":"YH Liao","year":"2005","unstructured":"Liao YH, Yuan J, Wang ZH, et al. Infectious tolerance to ADP\/ATP carrier peptides induced by anti-L3T4 monoclonal antibody in dilated cardiomyopathy mice. J Clin Immunol, 2005,25(4):376\u2013384","journal-title":"J Clin Immunol"},{"issue":"10","key":"2916_CR13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.autrev.2011.04.014","volume":"10","author":"F Cacciapaglia","year":"2011","unstructured":"Cacciapaglia F, Navarini L, Menna P, et al. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev, 2011,10(10):631\u2013635","journal-title":"Autoimmun Rev"},{"issue":"12","key":"2916_CR14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jacc.2013.05.035","volume":"62","author":"X Li","year":"2013","unstructured":"Li X, Zhang J, Huang J, et al; Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol, 2013,62(12):1065\u20131072","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2916_CR15","first-page":"263","volume":"6","author":"YL Wu","year":"2007","unstructured":"Wu YL, Gu CH, Xu GC, et al. Clinical observation of randomized double-blind and multicenter trial on Qiliqiangxin capsule in the treatment of chronic heart failure. Chin J Difficult Complicated Cases (Chinese), 2007,6(5):263\u2013266","journal-title":"Chin J Difficult Complicated Cases"},{"key":"2916_CR16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12906-016-1174-1","volume":"16","author":"J Sun","year":"2016","unstructured":"Sun J, Zhang K, Xiong WJ, et al. Clinical effects of a standardized Chinese herbal remedy, QiliQiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis. BMC Complement Altern Med, 2016,16:201","journal-title":"BMC Complement Altern Med"},{"key":"2916_CR17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3389\/fphar.2019.01046","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhu M, Zhang F, et al. Integrating pharmacokinetics study, network analysis, and experimental validation to uncover the mechanism of Qiliqiangxin capsule against chronic heart failure. Front Pharmacol, 2019,10:1046","journal-title":"Front Pharmacol"},{"issue":"1","key":"2916_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cellimm.2009.09.001","volume":"260","author":"H Xiao","year":"2009","unstructured":"Xiao H, Song Y, Li Y, et al. Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction. Cell Immunol, 2009,260(1):51\u201355","journal-title":"Cell Immunol"},{"issue":"5","key":"2916_CR19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","volume":"93","author":"P Richardson","year":"1996","unstructured":"Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation, 1996,93(5): 841\u2013842","journal-title":"Circulation"},{"issue":"33","key":"2916_CR20","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio AL, Pankuweit S, Arbustini E, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 2013,34(33):2636\u20132648, 2648a-2648d","journal-title":"Eur Heart J"},{"key":"2916_CR21","first-page":"9385472","volume-title":"Dis Markers","author":"ZH Wang","year":"2020","unstructured":"Wang ZH, Liao YH, Yuan J, et al. Continued elevation of plasma IL-4 and IL-17 predicts the progression from VMC to DCM. Dis Markers, 2020,9385472"},{"issue":"1","key":"2916_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick SA, Epelman S. Chronic heart failure and inflammation: what do we truly know? Circ Res, 2016,119(1):159\u2013176","journal-title":"Circ Res"},{"issue":"5","key":"2916_CR23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD, et al. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol, 2020,17(5):269\u2013285.","journal-title":"Nat Rev Cardiol"},{"key":"2916_CR24","doi-asserted-by":"crossref","first-page":"746494","DOI":"10.3389\/fphys.2021.746494","volume":"12","author":"M Reina-Couto","year":"2021","unstructured":"Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, et al. Inflammation in human heart failure: major mediators and therapeutic targets. Front Physiol, 2021,12:746494","journal-title":"Front Physiol"},{"issue":"5","key":"2916_CR25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1159\/000356581","volume":"32","author":"M Yu","year":"2013","unstructured":"Yu M, Hu J, Zhu MX, et al. Cardiac fibroblasts recruit Th17 cells infiltration into myocardium by secreting CCL20 in CVB3-induced acute viral myocarditis. Cell Physiol Biochem, 2013,32(5):1437\u20131450","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"2916_CR26","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/eji.201142209","volume":"42","author":"V Nindl","year":"2012","unstructured":"Nindl V, Maier R, Ratering D, et al. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur J Immunol, 2012,42(9):2311\u20132321","journal-title":"Eur J Immunol"},{"issue":"4","key":"2916_CR27","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/cvr\/cvr148","volume":"91","author":"T Yamashita","year":"2011","unstructured":"Yamashita T, Iwakura T, Matsui K, et al. IL-6-mediated Th17 differentiation through ROR\u03b3t is essential for the initiation of experimental autoimmune myocarditis. Cardiovasc Res, 2011,91(4):640\u2013648.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"2916_CR28","doi-asserted-by":"crossref","first-page":"85851","DOI":"10.1172\/jci.insight.85851","volume":"1","author":"JM Myers","year":"2016","unstructured":"Myers JM, Cooper LT, Kem DC, et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight, 2016,1(9):85851","journal-title":"JCI Insight"},{"issue":"5","key":"2916_CR29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.hlc.2012.12.002","volume":"22","author":"Q Javed","year":"2013","unstructured":"Javed Q, Murtaza I. Therapeutic potential of tumor necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ, 2013,22(5):323\u2013327","journal-title":"Heart Lung Circ"},{"issue":"15","key":"2916_CR30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.121.056628","volume":"144","author":"RJ Hajjar","year":"2021","unstructured":"Hajjar RJ, Leopold JA. Inflammation and heart failure: Friend or foe? Circulation, 2021,144(15):1241\u20131243","journal-title":"Circulation"},{"issue":"4","key":"2916_CR31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00395-013-0356-y","volume":"108","author":"U Hofmann","year":"2013","unstructured":"Hofmann U, Frantz S. How can we cure a heart \u201cin flame\u201d? A translational view on inflammation in heart failure. Basic Res Cardiol, 2013,108(4):356","journal-title":"Basic Res Cardiol"},{"issue":"10","key":"2916_CR32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","volume":"139","author":"BM Everett","year":"2019","unstructured":"Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation, 2019,139(10):1289\u20131299","journal-title":"Circulation"},{"issue":"10","key":"2916_CR33","first-page":"1006","volume":"11","author":"I Ka\u017eukauskien\u0117","year":"2021","unstructured":"Ka\u017eukauskien\u0117 I, Baltr\u016bnien\u0117 V, Rink\u016bnait\u0117 I, et al. Inflammation-related biomarkers are associated with heart failure severity and poor clinical outcomes in patients with nonischemic dilated cardiomyopathy. Life (Basel), 2021,11(10):1006","journal-title":"Life (Basel)"},{"issue":"10105","key":"2916_CR34","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T, et al; CANTOS Trial Group. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomized, double-blind, placebo-controlled trial. Lancet, 2017,390(10105):1833\u20131842","journal-title":"Lancet"},{"issue":"2","key":"2916_CR35","first-page":"98","volume":"42","author":"Chinese Society of Cardiology","year":"2014","unstructured":"Chinese Society of Cardiology; Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi (Chinese), 2014,42(2):98\u2013122","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"2","key":"2916_CR36","doi-asserted-by":"crossref","first-page":"R208","DOI":"10.1152\/ajpregu.90521.2008","volume":"296","author":"NE Hoch","year":"2009","unstructured":"Hoch NE, Guzik TJ, Chen W, et al. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol, 2009,296(2):R208\u2013R216","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"2916_CR37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2310\/JIM.0b013e31822ba7fb","volume":"59","author":"MK Tsai","year":"2011","unstructured":"Tsai MK, Jan RL, Lin CH, et al. Suppressive effects of imidapril on Th1- and Th2-related chemokines in monocytes. J Investig Med, 2011,59(7):1141\u20131146","journal-title":"J Investig Med"},{"issue":"35","key":"2916_CR38","doi-asserted-by":"crossref","first-page":"14948","DOI":"10.1073\/pnas.0903958106","volume":"106","author":"M Platten","year":"2009","unstructured":"Platten M, Youssef S, Hur EM, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17- mediated autoimmunity. Proc Natl Acad Sci USA, 2009,106(35):14948\u201314953","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2916_CR39","first-page":"170","volume":"13","author":"J Li","year":"2009","unstructured":"Li J, Yang P. Inhibition of periostin by Qiliqiangxin to improve ventricular remodeling in heart failure rats. Chin J Lab Diagnos (Chinese), 2009,13(2):170\u2013172","journal-title":"Chin J Lab Diagnos"},{"issue":"3","key":"2916_CR40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/FJC.0b013e31823f888f","volume":"59","author":"Y Zou","year":"2012","unstructured":"Zou Y, Lin L, Ye Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. J Cardiovasc Pharmacol, 2012,59(3):268\u2013280","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"2916_CR41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-022-04533-1","volume":"13","author":"J Lin","year":"2022","unstructured":"Lin J, Li Q, Jin T, et al. Cardiomyocyte IL-1R2 protects heart from ischemia\/reperfusion injury by attenuating IL-17RA-mediated cardiomyocyte apoptosis. Cell Death Dis, 2022,13(1):90","journal-title":"Cell Death Dis"},{"key":"2916_CR42","doi-asserted-by":"crossref","first-page":"109690","DOI":"10.1016\/j.cellsig.2020.109690","volume":"73","author":"T Yoshida","year":"2020","unstructured":"Yoshida T, Das NA, Carpenter AJ, et al. Minocycline reverses IL-17A\/TRAF3IP2-mediated p38 MAPK\/NF-kappaB\/iNOS\/ NO-dependent cardiomyocyte contractile depression and death. Cell Signal, 2020,73:109690","journal-title":"Cell Signal"},{"key":"2916_CR43","doi-asserted-by":"crossref","first-page":"109024","DOI":"10.1016\/j.intimp.2022.109024","volume":"110","author":"Q Long","year":"2022","unstructured":"Long Q, Li L, Yang H, et al. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol, 2022,110:109024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2916_CR44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20161702","volume":"214","author":"NL Diny","year":"2017","unstructured":"Diny NL, Baldeviano GC, Talor MV, et al. Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med, 2017,214(4):943\u2013957","journal-title":"J Exp Med"},{"issue":"7","key":"2916_CR45","first-page":"3042","volume":"23","author":"Q Li","year":"2019","unstructured":"Li Q, Ye WX, Huang ZJ, et al. Effect of IL-6-mediated STAT3 signaling pathway on myocardial apoptosis in mice with dilated cardiomyopathy. Eur Rev Med Pharmacol Sci, 2019,23(7):3042\u20133050","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"2916_CR46","first-page":"127","volume":"33","author":"HY Chang","year":"2017","unstructured":"Chang HY, Wang CC, Wu YW, et al. One-year outcomes of acute decompensated systolic heart failure in Taiwan: Lessons from TSOC-HFrEF Registry. Acta Cardiol Sin, 2017,33(2):127\u2013138","journal-title":"Acta Cardiol Sin"},{"issue":"12","key":"2916_CR47","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail, 2017, 19(12):1574\u20131585","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"2916_CR48","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021,42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"17","key":"2916_CR49","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/ HFSA Guideline for the management of heart failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 2022,79(17):e263\u2013e421","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"2916_CR50","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J, 2023,44(37):3503\u20133626","journal-title":"Eur Heart J"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-024-2916-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-024-2916-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-024-2916-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T12:21:49Z","timestamp":1734956509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-024-2916-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2916"],"URL":"https:\/\/doi.org\/10.1007\/s11596-024-2916-9","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}